Medicinal product name MabThera
Pharmaceutical form Concentrate for solution for infusion
Strength 500 mg 
Information from the MAH on shortages Not available
predicted availability date: Apr 9, 2025
Legal status Rx Prescription (Pr.)
KZSL1 Next lowest cost medicine
Summary of product characteristics, package leaflet and labeling text  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
Risk minimisation measuresIzglītojošie materiāli ārstam Izglītojošie materiāli ārstam
Izglītojošie materiāli pacientam Izglītojošie materiāli pacientam
Vēstule veselības aprūpes speciālistam Vēstule veselības aprūpes speciālistam
ATC code L01FA01 Antineoplastic agents

Medicinal products (1)

Availability of medicinal product Wholesalers Package size, content Primary packaging Maximum admissible pharmacy price (€ incl. VAT) Product No. Labelling
 Not available (according to the information provided by wholesalers)
predicted availability date: Apr 9, 2025
currently no information on availability from any wholesaler N1
(500 mg/50 ml)
Glass vial 1444.09 
KZSL1*
EU/1/98/067/002  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
* Indication about medicine on the List of state reimbursed medicines is just informative. Source of the information is the National Health Service. For details please visit the NHS website.

Registration information

Marketing authorisation No. EU/1/98/067/002
Date of authorisation Jun 2, 1998
Marketing authorisation holder, country Roche Registration GmbH, Germany